Pharmaceutical Belgium-based Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), says that, after an accelerated regulatory review process by the European Medicines Agency and following a positive CHMP opinion (The Pharma Letter July 23), the European Commission has approved the marketing authorization for Zytiga (abiraterone acetate), a novel, once-daily, oral, androgen biosynthesis inhibitor. 8 September 2011